COVINNOVATIONS TO PRESENT TO INVESTORS AT 2022 BIOTECH SHOWCASE

LAS VEGAS – Covinnovations™ has been invited to participate in the 2022 Biotech Showcase, an investor conference for innovators in medical, life sciences and other biotechnology industries, January 10-12, 2022. Covinnovations will highlight a revolutionary new treatment, CovArrest™, for hospitalized patients with severe COVID-19 symptoms. An earlier version of the drug significantly reduced hospital length of stay and has the potential to reach nearly 100% recovery. The Biotech virtual presentation can be accessed at www.informaconnect.com/biotech-showcase.

As the coronavirus pandemic infection rate continues to explode, investors will have the opportunity to participate in this groundbreaking treatment program that has proven to reduce symptom severity and mortality for late-stage COVID-19 patients. Covinnovations™ currently has a pending application for FDA Investigative New Drug (IND) authorization and is engaged in productive communications with the Biological Advance Research Development Agency funding for Phase 3 testing.

Covinnovations™ was founded Dr. Aury Nagy, M.D. FAANS, a practicing neurosurgeon in Las Vegas, who was motivated to help these patients while walking the halls of the COVID wing of a local hospital not long after the start of the Pandemic. “It was sobering to see one disease take so many lives,” he recalls. He spent the better part of seven months educating himself and conducting research that ultimately resulted in the development of CovArrest™.

COVID-19 causes death through a cytokine storm in the lungs, which causes acute respiratory distress syndrome, particularly among those with weakened immune systems or long-standing medical conditions. Only ~70% of ICU patients survive with the current treatment for this condition, which includes hospitalization with oxygen/intubation, steroids and other treatments like Remdesivir. CovArrest™ is a late-stage critical care treatment that suppresses the cytokine storm and ends viral replication at the cellular level. Early tests show a 68 percent decrease in mortality rate for oxygen-starved hospitalized COVID-19 patients who receive CovArrest™.

“It is astounding to consider that if CovArrest™ had been available, up to two-thirds of those who have died from COVID might have survived,” Dr. Nagy said. “Both base components of this treatment have more than 20 years of safety and efficacy history, so we anticipate broad acceptance and usage of CovArrest™.”

Investors in CovArrest™ will be able to participate in the development and production of what promises to be the standard of care treatment for all hospitalized COVID-19 patients in the U.S. and abroad who require oxygen support, resulting in millions of doses administered worldwide. The company currently is preparing for production and distribution of CovArrest™, and its clinical scientists have established trial protocols that are ready to deploy around the world.

About CovArrest ™

This new drug is composed of two current FDA-approved drugs that work synergistically to attack the same disease and are both metabolized by the same liver enzymes. One of the components of CovArrest™ showed significant success in a retrospective review completed in December 2020. This study demonstrated a 68% reduction in mortality (p<0.05) and a 37% reduction in length of hospital stay (p<0.01). The treated group and the control group both received standard of care treatment as of 6/2020. Patients in the group provided the drug had a 93.6% survival rate as compared to the control group which had a survival rate of 78.5%. Those who did not survive appeared to experience a resurgence of viral replication or an insufficiently suppressed immune response, leading to the addition of the second component of CovArrestTM. A subsequent cohort of 11 patients with the combined drug achieved 100% survival.